乌鸦传媒

In this exclusive 乌鸦传媒 video, , of the University of Texas MD Anderson Cancer Center in Houston, offers his thoughts on the data that might be presented at next year's American Society of Clinical Oncology (ASCO) annual meeting.

Following is a transcript of his remarks:

It's a good year for renal cell carcinoma. At ASCO, we've got some interesting follow-ups from clinical trials, like long-term follow-up from the testing pembrolizumab [Keytruda] plus lenvatinib [Lenvima] versus the control arm of sunitinib [Sutent], and ] testing pembrolizumab plus axitinib [Inlyta] versus the control arm of sunitinib.

And there have been also good trials coming out for the non-clear cell renal cell carcinoma space. It's exciting to see the non-clear cell renal cell carcinoma histology having trials, and it will be important in the future to have dedicated trials from now on for each of the non-clear cell renal cell carcinoma subtypes.

At ASCO 2024, we will possibly start seeing some more data about the efficacy of either monotherapy or combinations of HIF-2 [hypoxia-inducible factor-2] alpha inhibitors. This is a new therapeutic pathway for metastatic clear cell renal cell carcinoma, in particular based on the biology that is being explored a lot.

We will hopefully be seeing data, more data, about the rare renal cell carcinoma histologies as well.

Comment